Urinary angiotensinogen concentration as a novel marker of cardio-renal syndrome


Cite item

Full Text

Abstract

Urinary angiotensinogen concentration adequately reflects the activity of the kidney pool of renin-angiotensin-aldosterone system (RAAS). Experimental and clinical studies allow considering this indicant as a reliable early marker of cardio-renal syndrome, reflecting the formation and progression of kidney damage and characterizing the effectiveness of RAAS blockers

About the authors

- -

References

  1. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний // Вестник РАМН. 2003. № 11. С. 50-55.
  2. Gil P., Justo S., Castilla M.A. et al. Cardio-renal insufficiency: the search for management strategies. Curr. Opin Nephrol. Hypertens. 2005;14(5):442-447.
  3. De Jong P.E., Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109-2118.
  4. Whaley-Connel A., Pavey B.S., Chaundary K., et al. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther. Adv. Cardiovac. Dis. 2007;1(1):27-35.
  5. Baudin B. Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis. Pathol. Biol. (Paris). 2005;53(3):183-188.
  6. Pimenta E., Calhoun D.A. Primary aldosteronism: diagnosis and treatment. J. Clin. Hypertens. (Greenwich). 2006;8(12):887-893.
  7. Skott O. Renin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002;282:R937-R939.
  8. Rouleau J.C., Packer M., Moye L., et al. Prognostic value of neurohumoral activation in patients with acute myocardial infarction: effect of captorpil. J. Am. Coll. Cardiol. 1994;24(3):583-591.
  9. Roig E., Perez-Villa F., Morales M., et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21;53-57.
  10. Meade T.W., Cooper J.A., Peart W.S. Plasma rennin activity and ischemic heart disease. N. Engl. J. Med. 1993;329:616-619.
  11. Dzau V.J., Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994;89:493-498.
  12. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста-β1 как показатель прогрессирования хронического гломерулонефрита // Терапевтический архив. 2006. № 5. С. 9-14.
  13. Kim H.S., Krege J.H., Kluckman K.D., et al. Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. USA 1995;92:2735-2739.
  14. Tanimoto K., Sugiyama F., Goto Y., et al. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 1994;269(50):31334-31337.
  15. Ishida J., Sugiyama F., Tanimoto K., et al. Rescue of angiotensinogen-knockout mice. Biochem. Biophys. Res. Commun. 1998;252(3):610-616.
  16. Davisson R.L., Kim H.S., Krege J.H., et al. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J. Clin. Invest. 1997;99(6):1258-1264.
  17. Taniguchi K., Sugiyama F., Kakinuma Y., et al. Pathologic characterization of hypotensive C57BL/6J-agt: angiotensinogen-deficient C57BL/6J mice. Int. J. Mol. Med. 1998;1(3):583-587.
  18. Naber C.K., Siffert W. Genetics of human arterial hypertension. Minerva Med. 2004;95(5):347-356.
  19. Giner V., Corella D., Chaves F.J. et al. Renin-angiotensin system genetic polymorphisms and essential hypertension in the Spanish population. Med. Clin. (Barc.). 2001; 117(14): 525-529
  20. Castellano M., Glorioso N., Cusi D., et al. Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J. Hypertens. 2003;21(10):1853-1860.
  21. Borecki I.B., Province M.A., Ludwig E.H., et al. Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study. Ann. Epidemiol. 1997;7(1):13-21.
  22. Petrovic D., Bidovec M., Peterlin B. Gene polymorphisms of the renin-angiotensin-aldosterone system and essential arterial hypertension in childhood. Folia Biol. (Krakow). 2002;50(1-2):53-56.
  23. Suzuki Y., Tanemura M., Suzuki Y., et al. Is angiotensinogen gene polymorphism associated with hypertension in pregnancy? Hypertens. Pregnancy. 1999;18(3):261-271.
  24. Schunkert H., Hense H.W., Gimenez-Roqueplo A.P., et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension. 1997;29(2):628-633.
  25. Bhuiyan A.R., Chen W., Srinivasan S.R., et al. G-6A polymorphism of angiotensinogen gene modulates the effect of blood pressure on carotid intima-media thickness. The Bogalusa Heart Study. Am. J. Hypertens. 2007;20(10):1073-1078.
  26. Schmidt R., Schmidt H., Fazekas F., et al. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension. 2001;38(1):110-115.
  27. Schmidt H., Fazekas F., Kostner G.M., et al. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke. 2001;32(2):405-412.
  28. Young R.P., Chan J.C., Critchley J.A. et al. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. Diabetes Care. 1998;21(3):431-437.
  29. Fabris B., Bortoletto M., Candido R., et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J. Hypertens. 2005;23(2):309-316.
  30. Ludwig E.H., Borecki I.B., Ellison R.C., et al. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. Ann. Epidemiol. 1997;7(1):3-12.
  31. Ingelfinger J.R., Schunkert H., Ellison K.E. et al. Intrarenal angiotensinogen: localization and regulation. Pediatr. Nephrol. 1990;4(4):424-428.
  32. Gociman B., Rohrwasser A., Lantelme P., et al. Expression of angiotensinogen in proximal tubule as a function of glomerular filtration rate. Kidney Int. 2004;65(6):2153-2160.
  33. Kobori H., Nishiyama A., Abe Y., et al. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003;41(3):592-597.
  34. Miyata K., Ohashi N., Suzaki Y., et al. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 2008;35(8):922-927.
  35. Pedraza-Chaverri J., Cruz C., Ibarra-Rubio M.E., et al. Urinary excretion of renin and angiotensinogen in nephrotic rats. Nephron. 1991;57(1):106-108.
  36. Kobori H., Harrison-Bernard L.M., Navar L.G. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension. 2001;37(5):1329-1335.
  37. Kobori H., Nishiyama A., Harrison-Bernard L.M., et al. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension. 2003;41(1):42-49.
  38. Lantelme P., Rohrwasser A.,Vincent M., et al. Significance of urinary angiotensinogen in essential hypertension as a function of plasma renin and aldosterone status. J. Hypertens. 2005;23(4):785-792.
  39. Kobori H., Alper B., Shenava R., et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009;53(2):344-350.
  40. Ohashi N., Yamamoto T., Huang Y., et al. Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats. Am. J. Physiol. Renal. Physiol. 2008;295(5):F1512-F1518.
  41. Yamamoto T., Nakagawa T., Suzuki H., et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2007;18(5):1558-1565.
  42. Kobori H., Ohashi N., Katsurada A., et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney disease. J. Am. Soc. Hypertens. 2008;2(5):349-354.
  43. Katsurada A., Hagiwara Y., Miyashita K., et al. Novel sandwich ELISA for human angiotensinogen. Am. J. Physiol. Renal. Physiol. 2007;293(3):F956-F960.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies